Under construction – not a live service
Sign in
Not yet taking people in GermanyPhase 2

Tests pembrolizumab as first treatment for advanced Hodgkin lymphoma

Tests pembrolizumab with chemotherapy and radiotherapy in adults with advanced Hodgkin lymphoma.

Plain-language title generated from the registry record
Registry title: Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Key facts

Where
Cologne, GermanySee the site
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Source: NCT06045195, who can take part

Where in Germany

  • 1st Department of Medicine, Cologne University HospitalCologne, GermanyNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Cologne
Trial code
NCT06045195
Record updated
6 April 2025
Original description
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of careRead full original descriptionShow less

Phase II Trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care

Main Inclusion Criteria:; age 18-60; advanced stage classical Hodgkin Lymphoma; no previous treatment for cHL; Main Exclusion Criteria:; Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma; Chemotherapy or radiotherapy in medical history; Prior or concurrent disease that prevents treatment according to protocol.

ClinicalTrials.gov NCT06045195